HHM Wealth Advisors LLC Has $830,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

HHM Wealth Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,002 shares of the company’s stock after selling 89 shares during the period. HHM Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $830,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Brentview Investment Management LLC raised its position in Johnson & Johnson by 6.1% during the first quarter. Brentview Investment Management LLC now owns 21,356 shares of the company’s stock valued at $3,542,000 after buying an additional 1,227 shares during the period. Intrinsic Value Partners LLC acquired a new position in Johnson & Johnson during the first quarter valued at $203,000. MGO One Seven LLC raised its position in Johnson & Johnson by 5.8% during the first quarter. MGO One Seven LLC now owns 80,891 shares of the company’s stock valued at $13,415,000 after buying an additional 4,449 shares during the period. Cordatus Wealth Management LLC raised its position in Johnson & Johnson by 5.6% during the first quarter. Cordatus Wealth Management LLC now owns 33,669 shares of the company’s stock valued at $5,583,000 after buying an additional 1,791 shares during the period. Finally, Atlas Wealth LLC raised its position in Johnson & Johnson by 12.2% during the first quarter. Atlas Wealth LLC now owns 2,086 shares of the company’s stock valued at $346,000 after buying an additional 226 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $167.31 on Thursday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average is $156.93 and its two-hundred day moving average is $156.30. The company has a market cap of $402.94 billion, a P/E ratio of 17.89, a P/E/G ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.82 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.11%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research reports. Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Royal Bank Of Canada upped their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Finally, Bank of America upped their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.